Clinical Presentation and Treatment Outcomes of Children and Adolescents With Pheochromocytoma and Paraganglioma in a Single Center in Korea

Hyojung Park†, Min-Sun Kim†, Jiwon Lee1, Jung-Han Kim2, Byong Chang Jeong3, Sanghoon Lee2, Suk-Koo Lee2, Sung Yoon Cho1‡ and Dong-Kyu Jin1‡

1 Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2 Department of Pediatric Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3 Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Purpose: Pheochromocytoma (PCC) and paraganglioma (PGL) (PPGL) are rare neuroendocrine tumors, and data on managing these conditions in children and adolescents are lacking. The objective of this study was to demonstrate the clinical presentation and treatment outcomes in children and adolescents with PPGL in a single tertiary care center in Korea.

Methods: This retrospective study included 23 patients diagnosed with PCC (n = 14) and PGL (n = 9) before the age of 21 at Samsung Medical Center (from June 1994 to June 2019). We describe age, gender, family history, clinical characteristics, laboratory findings, pathologic findings, therapeutic approaches, and treatment outcomes.

Results: Of the 23 patients, 14 had PCC and nine had PGL. The median age at diagnosis was 16.8 years (range, 6.8–20.8 years). The common presenting symptoms were hypertension (n = 10), headache (n = 9), palpitation (n = 4), and sweating (n = 4). The plasma or 24-hour urine catecholamine and/or metabolite concentrations were markedly elevated in 22 patients with PPGL, but were normal in one patient with carotid body PGL. All tumors were visualized on computed tomography. Genetic tests were performed in 15 patients, and seven patients showed mutations in RET (n = 3), SDHB (n = 3), and VHL (n = 1). All patients underwent surgery, and complete excision was performed successfully. Three patients with metastasis underwent postoperative adjuvant therapy.

Conclusion: This study suggests that pediatric PPGL tends to be extra-adrenal and bilateral and shows a higher potential for genetic mutations. Considering the hereditary predisposition of pediatric PPGL, genetic screening tests are strongly recommended, and...
INTRODUCTION

Pheochromocytoma (PCC) and paraganglioma (PGL) (PPGL) are rare neoplasms, which arise from chromaffin cells that release catecholamines, including epinephrine (EPI), norepinephrine (NE), and dopamine (1). PCCs are located in the adrenal medulla, whereas PGLs arise in extra-adrenal locations, such as the sympathetic/parasympathetic ganglia (1, 2). Although the incidence of PPGL in the pediatric population is 0.2–0.5 cases per million, they are the most common endocrine tumors in childhood and account for 0.5–1% of pediatric hypertensive cases (3–5). The average age at diagnosis is 11–13 years for pediatric PPGL, with the incidence rate in males being twice that of the rate in females (1). The symptom triad of PPGL includes headache, sweating, and palpitation (6). In children, persistent hypertension is the most frequent symptom, unlike the paroxysmal hypertension observed in adults (1, 6, 7). Other symptoms of PPGL include anxiety, weight loss, visual disturbance, polyuria, and polydipsia (1, 6, 7). In adults, the “rule of 10%” for PGLs implies that 10% are malignant, 10% are bilateral, 10% are extra-adrenal, 10% are hereditary, and 10% are in children (8). With advancements in diagnostic techniques and genetic testing, the prevalence of bilateral, extra-adrenal, hereditary, and metastatic PPGLs has changed since the original “rule of 10%” for PGL (9). It has been reported that 50–70% of pediatric PPGL cases are associated with germline mutations in known susceptibility genes (10). The standard treatment for PPGL is total adrenalectomy (11). Unlike other tumors, there are no clinical, biochemical, or histopathological criteria for malignant PPGL (12, 13). The 2017 World Health Organization (WHO) classification has defined malignant PPGL as a metastatic disease that is histologically diagnosed by the presence of chromaffin tissues in organs that usually lack chromaffin cells (14). However, data for pediatric PPGL are limited, and the clinical management of PPGL in children and adolescents is usually extrapolated from adult data (8). Hence, the objective of this study was to demonstrate the clinical presentation and treatment outcomes of children and adolescents with PPGL in a single tertiary care center in Korea.

RESULTS

Clinical Presentation and Diagnostic Evaluations of Patients With PPGL

Of the 23 study patients, 14 patients (10 male and four female patients) had PCCs, and nine patients (five male and four female patients) had PGLs. The median age at diagnosis was 16.8 years (range, 6.8–20.8 years). Clinical presentations and diagnostic evaluations of the 23 patients with PPGL are shown in Table 1. The most common presenting symptoms were hypertension (n = 10), headache (n = 9), palpitation (n = 4), and sweating (n = 4), listed in the order of frequency. Three patients were incidentally diagnosed with PPGL during general health screening. The plasma or 24-hour urine catecholamine and/or metabolite concentrations were markedly elevated in 22 patients with PPGL, but were normal in one patient with carotid body PGL. The 24-hour urine MN or EPI concentrations were mainly elevated in PCC, but not PGL. Similarly, the plasma NMN or NE concentrations were higher in PGL cases than in PCC cases (Figure S1). After surgery, the concentrations of catecholamines and their metabolites normalized in all patients. CT was the most commonly utilized diagnostic tool in our study. All tumors were visualized on CT. To detect metastatic or multifocal disease, functional imaging with MIBG scintigraphy or PET was performed in conjunction with CT or MRI. In the PCC group, five patients had a tumor on the bilateral adrenal gland and nine patients had a unilateral mass. Most PGLs occurred along the
sympathetic chain in the retroperitoneum. Only one patient with PGL had a tumor in the carotid bifurcation of the neck. The median maximal diameter of the tumors was 4.75 cm (range, 1.5–19.0 cm).

**Genetic Evaluation of PPGL**

Genetic tests were performed in 15 patients, and mutations related to PPGL were identified in seven patients (Table 2). Among patients with PCCs, three had an RET mutation and one had a VHL mutation. Among patients with PGL, three had an SDHB mutation. Two patients with an RET mutation had bilateral PCC and underwent total thyroidectomy because of medullary thyroid carcinoma. The other patient with an RET mutation had unilateral PCC, autoimmune thyroiditis, and type 1 diabetes mellitus. The patient with a VHL mutation had cerebellar hemangioblastoma 6 years after bilateral adrenalectomy. Two of the three PGL patients with SDHB mutations had metastasis identified at diagnosis or during follow-up and received adjuvant therapy. The other patient, who was diagnosed with PGL and had an SDHB mutation, did not show other abnormalities, such as metastasis, during follow-up.

**Therapeutic Approaches and Treatment Outcomes**

All patients underwent surgery and complete excision successfully. In our cohort, all patients started to take an alpha-blocker 1 to 2 weeks before surgery to prevent hypertensive crisis and hypotensive shock. A beta-blocker was added to control tachyarrhythmia or reflex tachycardia in eight patients. As a result, hypertensive crisis, stroke, arrhythmia, or myocardial infarction did not occur during or after surgery. Nineteen patients underwent laparotomy, and four patients underwent laparoscopic surgery. All patients had negative microscopic margins in their pathological samples. Capsular invasion was identified in four patients with PCC and in two patients with PGL. Vascular invasion was identified in one patient with PCC and one with PGL. Lymphatic invasion was identified in only one PGL patient. There was no mortality related to surgery, postoperative hypotension, or hypoglycemia. One patient had renal atrophy due to left renal vein thrombosis. The median follow-up period was 39 months (range, 6 months to 19.9 years). Three patients with PCC showed bilateral metachronous lesions, and the time to recurrence was 7, 42, and 51 months in these three patients. In patients with PGL, no recurrence occurred during the follow-up period. One of the 14 patients with PCC and two of the nine patients with PGL were classified as having metastasis. The sites of metastasis were mainly the lungs, bones, and lymph nodes. One patient with PGL showed metachronous metastasis after 8 years and 11 months from tumorectomy. The other patient with PGL and one patient with PCC had synchronous metastasis at diagnosis. These three patients with metastasis underwent adjuvant therapy. One patient with PCC was treated with chemotherapy and transferred to another hospital. One patient with PGL is currently receiving $^{131}$I MIBG treatment followed by chemotherapy. The other with PGL received chemotherapy, radiotherapy, and MIBG treatment. No patient died during the follow-up period. Therapeutic approaches and treatment outcomes are summarized in Table 3.

---

**TABLE 1 | Clinical presentations and diagnostic evaluation of patients with PPGL.**

| Age at diagnosis, median (range) years | Total (23) | PCC (14) | PGL (9) |
|--------------------------------------|-----------|---------|--------|
|                                       | 16.8 (6.8–20.6) | 17.6 (13.3–20.3) | 13.7 (6.8–20.8) |

| Gender, n (%) | M | F |
|---------------|---|---|
| M             | 15 (65.2%) | 8 (34.8%) |
| F             | 10 (71.4%) | 4 (28.6%) |
| M             | 5 (55.6%) | 4 (44.4%) |
| F             | 5 (55.6%) | 4 (44.4%) |

| Main presenting symptoms | Elevated | Normal |
|--------------------------|----------|--------|
| Hypertension             | 22 (95.7%) | 1 (4.3%) |
| Headache                 | 14 (100%) | 8 (88.9%) |
| Palpitation              | 8 (88.9%) | 1 (11.1%) |
| Sweating                 | 0        | 1 |
| Incidental               | 1        | 1 |

| Imaging performed to diagnose | CT | MRI | MIBG | PET |
|-------------------------------|----|-----|------|-----|
| Unilateral 9 (64.3%)         | 22 | 2   | 8    | 9   |
| Bilateral 5 (35.7%)          | 13 | 0   | 4    | 2   |
| Retropertitoneum 8 (88.9%)   |    |     | 1    |     |

| Location of primary tumor, n (%) | Unilateral | Bilateral | Retropertitoneum |
|----------------------------------|------------|-----------|-----------------|
| Hypertension                     | 3 (13%)    | 1 (7.1%)  | 2 (22.2%)       |
| Palpitation                      | 3 (13%)    | 0 (0%)    |                 |

PPGL, PCC and PGL; PCC, pheochromocytoma; PGL, paraganglioma; CT, computed tomography; MRI, magnetic resonance imaging; MIBG, meta-iodobenzylguanidine scintigraphy; PET, positron emission tomography; M, male; F, female.
TABLE 2 | Clinical characteristics of patients with PPGL.

| Patients     | Sex | Age at diagnosis (y) | Initial presentation | BP at diagnosis (mmHg) | Tumorlocation | Maximal tumor diameter (cm) | Surgical approach | Post-operative treatment | Follow-up duration (y) | Recurrence | Metastasis | Family history | Co-morbidity | Mutation |
|--------------|-----|----------------------|----------------------|------------------------|---------------|----------------------------|------------------|--------------------------|------------------------|------------|------------|----------------|--------------|----------|
| PCC1         | M   | 19.3                 | Incidental           | 148/87                 | Lt            | 4.5                        | Lapa             | N                        | 3.3*                   | N          | N          | N              | ND           |          |
| PCC2         | M   | 13.3                 | HTN                  | 135/79                 | BL            | 4.5                        | Open             | Y                        | Transfer               | Y          | N          | N              | NA           |          |
| PCC3         | M   | 16.4                 | HTN                  | 158/76                 | BL            | 5                          | Open             | Y                        | 11.4                   | N          | N          | N              | Cerebellar HB | VHL      |
| PCC4         | F   | 18.3                 | HTN                  | 145/99                 | Lt            | 3                          | Open             | N                        | 9.8                    | N          | N          | N              | NA           |          |
| PCC5         | M   | 13.6                 | HA                   | 115/68                 | BL            | 5                          | Open             | Y                        | 7                      | N          | N          | N              | Hypothyroid   | ND       |
| PCC6         | M   | 18.5                 | Incidental           | 129/69                 | Lt            | 3                          | Lapa             | N                        | 3.1                    | N          | N          | N              | ND           |          |
| PCC7         | F   | 13.5                 | HA                   | 165/125                | Lt            | 4.3                        | Open             | Y                        | 2.7                    | N          | N          | N              | ND           |          |
| PCC8         | F   | 16.5                 | Palpitation          | 160/110                | Lt            | 10.5                       | Open             | N                        | 2.3                    | N          | N          | N              | ND           |          |
| PCC9         | M   | 20.2                 | HTN                  | 155/101                | BL            | 6.5                        | Lapa             | Y                        | 7.9                    | Y          | N          | N              | MTC          | RET      |
| PCC10        | M   | 20.3                 | Palpitation          | 102/63                 | Lt            | 9                          | Open             | N                        | 4                      | N          | N          | N              | ND           |          |
| PCC11        | M   | 20                   | HTN                  | 133/74                 | Rt            | 7.5                        | Open             | CT                       | 13.5                   | N          | Y          | N              | NA           |          |
| PCC12        | M   | 16.8                 | HTN                  | 160/110                | Lt            | 7.5                        | Open             | N                        | 12.8*                  | N          | N          | N              | NA           |          |
| PCC13*       | F   | 19.9                 | HA                   | 115/56                 | BL            | 3.8                        | Open             | Y                        | 14.1*                  | Y          | N          | N              | NA           | RET      |
| PCC14        | M   | 16.9                 | Vomiting             | 140/88                 | Rt            | 6.7                        | Lapa             | N                        | 0.8                    | N          | N          | N              | Autoimmune thyroiditis | DM    |
| PGL15        | M   | 18.3                 | Dyspnea              | 145/75                 | RP            | 7                          | Open             | Y                        | 0.7*                   | N          | N          | N              | ND           |          |
| PGL16        | M   | 13.7                 | HTN                  | Systolic BP>160        | RP            | 3                          | Open             | N                        | 0.6*                   | N          | N          | N              | ND           |          |
| PGL17        | F   | 15.5                 | HTN                  | 130/85                 | RP            | 4.5                        | Open             | N                        | 1.5*                   | N          | N          | N              | NA           |          |
| PGL18        | M   | 20.7                 | Abdominal mass       | 127/75                 | RP            | 19                         | Open             | CT, RT, MIBG             | 19.9                   | N          | Y          | N              | SDHB         |          |
| PGL19        | F   | 9.3                  | HTN                  | 160/110                | RP            | 6.5                        | Open             | N                        | 10.3                   | N          | N          | N              | DCM           | ND       |
| PGL20        | F   | 7.3                  | Abdominal mass       | 121/60                 | RP            | 9.5                        | Open             | CT, MIBG                 | 3                      | N          | Y          | N              | SDHB         |          |
| PGL21        | M   | 20.8                 | Neck mass            | 122/60                 | Carotid       | 5                          | Open             | N                        | 0.5*                   | N          | N          | N              | ND           |          |
| PGL22        | M   | 12.8                 | Incidental           | 106/50                 | RP            | 4.3                        | Open             | N                        | 0.5*                   | N          | N          | N              | SDHB         |          |
| PGL23        | F   | 6.8                  | HTN                  | 160/110                | RP            | 1.5                        | Open             | N                        | 3.1                    | N          | N          | N              | ND           |          |

PPGL, PCC and PGL: PCC, pheochromocytoma; PGL, paraganglioma; M, male; F, female; y, years; HTN, hypertension; HA, headache; BP, blood pressure; Lt, left; BL, bilateral; Rt, right; RP, retroperitoneum; Lapa, laparoscopic; Y, yes; N, no; CT, chemotherapy; RT, radiotherapy; MIBG, metaiodobenzylguanidine scintigraphy; HB, hemangioblastoma; DCM, dilated cardiomyopathy; MTC, medullary thyroid carcinoma; DM, diabetes mellitus; ND, not detected; NA, not available; VHL, Von Hippel Landau; SDHB, succinate dehydrogenase complex subunit B.

*: positive family history (mother and uncle) #: this information is based on the active monitoring period.
TABLE 3 | Therapeutic approaches and treatment outcomes.

|                      | Total     | PCC       | PGL       |
|----------------------|-----------|-----------|-----------|
| Surgical treatment, n (%) |           |           |           |
| Laparoscopic         | 4 (17.4%) | 4 (26.6%) | 0         |
| Open                | 19 (82.6%)| 10 (71.4%)| 9 (100%)  |
| Chemotherapy, n (%)  | 3 (13%)   | 1 (7.1%)  | 2 (22.2%) |
| Radiotherapy, n (%)  | 1 (4.3%)  | 0         | 1 (11.1%) |
| MIBG, n (%)          | 2 (8.7%)  | 0         | 2 (22.2%) |

PCC, pheochromocytoma; PGL, paraganglioma; MIBG, metaiodobenzylguanidine scintigraphy.

DISCUSSION

This study describes the clinical presentation and treatment outcomes of PPGL in children and adolescents.

Owing to the rarity of PPGL, specific guidelines have not been adequately described for the pediatric population in the literature. In this population, the presentation of PPGL ranges from ambiguous symptoms to hypertensive crisis.

Symptomatology depends on the type of catecholamines secreted by PPGL (15, 16). The surge of catecholamines may be continuous or intermittent from the PPGL, resulting in various manifestations. Patients with NE-secreting tumors generally show persistent hypertension, whereas those with EPI-secreting tumors exhibit paroxysmal hypertension (15–17). However, PPGL can also present with nonspecific symptoms or an incidental mass. A retroperitoneal mass in children is likely to be mistaken for Wilms’ tumor or neuroblastoma rather than PPGL. Thus, the diagnosis of PPGL is based on the clinical presentation and the elevation of catecholamines or their metabolites in plasma or urine (6). The secretion of EPI is usually limited to PCC rather than PGL because PGL predominantly secretes NE. As PCCs can secrete both NE and EPI owing to the phenylethanol-N-methyltransferase enzyme, concentrations of EPI and its metabolite, MN, are elevated. As NE is mainly secreted in PGLs, concentrations of MN and EPI are not elevated (4, 17, 18). The small number of patients with PCC and PGL was a drawback in the determination of statistically significant differences in biochemical profiles between PCC and PGL. In our patients with PGL, the concentrations of EPI and MN in plasma or 24-hour urine were not as high as those in patients with PCC (Figure S1). In our study, plasma or 24-hour urine catecholamine and/or metabolite concentrations were markedly elevated in 22 patients with PPGL, but were normal in one patient with carotid body PGL. Carotid body PGL presents with a bulging neck mass and is a nonsecreting tumor. Head and neck PGLs from parasympathetic tissue are mostly chromaffin-negative tumors, and only 4% of parasympathetic PGLs secrete catecholamines (19). Recently, measurement of plasma or urine MN and NMN concentrations has been recommended as the most sensitive test for PPGL diagnosis (1, 4). CT or MRI has been recommended owing to their similar sensitivity in localizing pediatric PPGL (90–100%) (1, 18, 20). In our study, all tumors were visualized on CT. MRI is recommended especially in patients with metastatic PPGL, patients with surgical clips, and in pediatric patients to avoid radiation exposure. MRI is superior to CT for identifying the vascular structures of PCC (1). More recently, functional imaging with MIBG and PET has been complemented with CT or MRI to detect metastasis and recurrence and to evaluate tumor response to adjuvant therapy (1, 18, 20).

Up to 70–80% of pediatric patients with PPGL have an associated germline mutation, which may or may not be hereditary in nature or associated with a genetic syndrome (21). Approximately 40% of pediatric patients with PPGL have a hereditary disposition, and MEN2, VHL, NF1, and SDHx constitute the best-known genetic syndromes associated with PPGL. Considering this strong association, genetic testing is recommended in all children and adolescents with PPGL (22, 23). VHL is the major gene in children with PCC, and SDHB is associated with PGL. In particular, SDHx genes are associated with metastatic potential in PPGL (24).

Fifteen patients (65.2%) underwent genetic testing for mutations in PPGL-susceptibility genes; a pathogenic mutation was found in seven of them (46.7%). Because this retrospective study covers a long period, genetic screening was not proposed as a mandatory test for all patients. We identified known pathogenic mutations in VHL, RET, and SDHB in seven patients. A new analysis by next-generation sequencing with a panel including all identified PPGL-susceptibility genes should be considered to identify a pathogenic mutation in patients with previous negative genetic testing results.

Preoperative antihypertensive preparation is essential in PPGL surgery to avoid blood pressure fluctuations or a hypertensive crisis (1, 16). In children, phenoxybenzamine is widely recommended as an alpha-blocker. A high sodium diet and fluids totaling 1.5 times maintenance are required to maintain intravascular volume before surgery (1).

The definite treatment of PPGL is surgical resection. The surgical approach for a PPGL should be planned according to the secretion status of the tumor, the presence of bilateral lesions, and the surgeon’s experience. In the past, laparotomy was the main surgical procedure in our center to minimize risk of recurrence and metastasis based on the surgeon’s judgement. Recently, minimally invasive laparoscopic excision has been recommended in PPGL if there is no finding of multiple lesions, infiltration, metastasis, or vascular invasion around the tissue (4, 9, 25, 26). Cortical-sparing surgery is preferred in children to avoid lifelong glucocorticoid and mineralocorticoid replacement after bilateral adrenalectomy (4, 25–27). In our study, all patients showed a resectable lesion and underwent surgical resection successfully. No patients underwent adrenocortical-sparing surgery.

Systemic cytotoxic chemotherapy with cyclophosphamide, vincristine, and dacarbazine is indicated in patients with unresectable and rapidly progressive metastatic PPGL (26). In our study, although three patients who received chemotherapy showed mild anorexia and neutropenic fever, they did not show severe adverse effects such as catecholamine crisis. All patients underwent adrenalectomy in our study, and the proportion of patients with synchronous metastasis at diagnosis was lower.
(n=2) than that in other studies (28, 29). The higher survival rate compared to that in other studies (100 vs 72–97%) seems to be attributed to these factors (6, 10). However, long-term monitoring should be performed because late events could still occur.

Two patients (PCC 5 and PGL 19) were diagnosed with dilated cardiomyopathy. Excessive catecholamine can stimulate cardiac myocytes and lead to myopathy. Both patients presented with headache and hypertension. After surgery, their blood pressure was stabilized and remained within normal limits without antihypertensive drugs. Their cardiac function improved, and they did not have any features of cardiac failure thereafter.

Advancements in diagnostic techniques and genetic testing have broken the “rule of 10%” in PPGL. In recent years, more than 50% of pediatric PPGL have been reported with germline mutations in known susceptibility genes (10). As reported in several studies, pediatric PPGL is characterized by extra-adrenal, bilateral, and various phenotypes, indicating the differences in disease presentation in children and adults. In a large study, children showed higher prevalence of hereditary (80.4 vs. 52.6%), extra-adrenal (66.3 vs. 35.1%), multifocal (32.6 vs. 13.5%), metastasis (49.5 vs. 29.1%), and recurrent (29.5 vs. 14.2%) PPGLs than did adults (29). In another review of pediatric PPGL, 10% were metastatic, 20% were synchronous bilateral, 30% were extra-adrenal, and 40% were familial (28). Our study showed comparable results. First, the proportion of extra-adrenal was 39.1% (9/23) in our study. Second, the incidence of bilateral PCC was 35.7% (5/14). Third, 60% (3/5) of patients with PGL who had undergone genetic testing were identified as having the SDHB mutation, while 40% (4/10) of patients with PCC were confirmed with genetic mutations. Lastly, the rate of metastasis in our study was 7.1% (1/14) for PCC and 22.2% (2/9) for PGL. These results are consistent with the fact that PGL has a greater metastatic potential (12).

This study has several limitations. As PPGL is rare in children and adolescents, the size of the study population was insufficient for statistical analysis. Routine genetic testing could not be conducted consistently in all patients. For these reasons, the detection rate of genetic mutations may be inaccurate. We need to perform genetic tests for patients who have not had this testing done in the past. Moreover, a new analysis by next-generation sequencing with a panel including all identified PPGL-susceptibility genes can also identify a pathogenic mutation in patients with previous negative genetic testing results. Lastly, as this study examined rare, pediatric neuroendocrine diseases in a single large center, a multicenter study is needed to obtain more information.

CONCLUSION

PPGLs are rare neuroendocrine tumors, and experience managing pediatric PPGLs is not extensive. This study suggests that pediatric PPGL tends to be extra-adrenal and bilateral and shows a higher potential for genetic mutations. Considering the hereditary predisposition of pediatric PPGL, genetic screening tests are strongly recommended, and lifelong follow-up is needed to detect recurrence and metastasis. Further research with a larger sample size and routine genetic screening is needed to better understand the genetic conditions and long-term prognosis of PPGL.

DATA AVAILABILITY STATEMENT

The original contributions presented in the article are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

Written informed consent was obtained from patients and the parents of each patient. The Institutional Review Board at Samsung Medical Center approved this study (IRB file number: 2020-03-202).

AUTHOR CONTRIBUTIONS

HP, SC, and D-KJ contributed to the conception and design of the study. HP and M-SK organized the database. M-SK and JL performed the manual segmentation. HP, M-SK, and JL performed the statistical analysis. HP wrote the first draft of the manuscript. SC, SL, S-KL, and J-HK wrote sections of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by a grant from Samsung Medical Center (GFO3200061).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2020.610746/full#supplementary-material

Supplementary Figure 1 | Plotting of biochemical values in patients with PPGL. Untilled and filled squares represent biochemical values in PCC within and out of normal range, respectively. Untilled and filled circles represent biochemical values in PGL within and out of normal range, respectively. Normal ranges of each biochemical value were obtained from the Tietz textbook of Clinical Chemistry & Molecular Diagnostics, 5th ed (31). PPGL, PCC and PGL; PCC, pheochromocytoma; PGL, paraganglioma; NMN, normetanephrine; MN, metanephrine; NE, norepinephrine; EPI, epinephrine.
REFERENCES

1. Bholah R, Bunchman TE. Review of Pediatric Pheochromocytoma and Paraganglioma. Front Pediatr (2017) 5:155. doi: 10.3389/fped.2017.00155
2. Neumann HPH, Young WF Jr., Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med (2019) 381:552–65. doi: 10.1056/NEJMra1806651
3. Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci (2006) 1073:30–7. doi: 10.1196/annals.1353.003
4. Çiftci AO, Tanyel FC, Senocak ME, Büyükpamukçu N. Pheochromocytoma in children. J Pediatr Surg (2001) 36:447–52. doi: 10.1053/jpsu.2001.21612
5. Ross JH. Pheochromocytoma. Special considerations in children. Urol Clin North Am (2000) 27:393–402. doi: 10.1016/s0091-6738(00)70088-4
6. Pham TH, Moir C, Thompson GB, Zarroug AE, Hamner CE, Farley D, et al. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. Pediatrics (2006) 118:1109–17. doi: 10.1542/peds.2005-2299
7. Eren E, Sağlam H, Calışkan Y, Kırıstoğlu I, Tarim O. Pediatric patients with pheochromocytoma: Experience of a tertiary health center. Pediatr Int (2015) 57:875–9. doi: 10.1111/ped.12664
8. Peard L, Cost NG, Saltzman AF. Pediatric pheochromocytoma: current status of diagnostic imaging and treatment procedures. Curr Opin Urol (2019) 29:493–9. doi: 10.1097/mou.0000000000000650
9. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Pheochromocytoma. Lancet (2005) 366:665–75. doi: 10.1016/s0140-6736(05)67139-5
10. de Terssant M, Genere L, Freycon C, Villebasse S, Abbas R, Barlier A, et al. Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE). J Endocr Soc (2020) 4:bva039. doi: 10.1210/jendos/bva039
11. Board PDQATE. Pheochromocytoma and Paraganglioma Treatment (PDQ®): Health Professional Version. In: PDQ Cancer Information Summaries. Bethesda (MD: National Cancer Institute) (US 2002).
12. Chrisoulioudou A, Kaltzas G, Ilias I, Grossman AB. The diagnosis and management of malignant pheochromocytoma and paraganglioma. Endocr Relat Cancer (2007) 14:569–85. doi: 10.1677/erc-07-0074
13. Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, et al. European Society of Endocrinology Clinical Practice Guidance for long-term follow-up of patients operated on for a pheochromocytoma or a paraganglioma. Eur J Endocrinol (2016) 174:G1–10. doi: 10.1530/eje-16-0033
14. Lam AK. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol (2017) 28:213–27. doi: 10.1007/s12022-017-9484-5
15. Challis BG, Casey RT, Simpson HL, Gurnell M. Is there an optimal preoperative management strategy for pheochromocytoma/paraganglioma? Clin Endocrinol (Oxf) (2017) 86:163–7. doi: 10.1111/cen.13352
16. Isaacs M, Lee P. Preoperative alpha-blockade in pheochromocytoma and paraganglioma: is it always necessary? Clin Endocrinol (Oxf) (2017) 86:309–14. doi: 10.1111/cen.13284
17. Eisenhofer G. Screening for pheochromocytomas and paragangliomas. Curr Hypertens Rep (2012) 14:130–7. doi: 10.1007/s11906-012-0246-y
18. Kiernan CM, Solorzano CC. Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, and Treatment. Surg Oncol Clin N Am (2016) 25:119–38. doi: 10.1016/j.soc.2015.08.006
19. Eisenhofer G, Lenders JW, Pacak K. Biochemical diagnosis of pheochromocytoma. Front Horm Res (2004) 31:76–106. doi: 10.1159/000074659
20. Antonio K, Valdez MMN, Mercado-Asis L, Táb, D, Pacak K. Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surg (2020) 9:105–23. doi: 10.21037/gs.2019.10.25
21. Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas (2010) 39:775–83. doi: 10.1097/MPA.0b013e3181cb4a0
22. Bausch B, Wellner U, Bausch D, Schiavi F, Barontini M, Sanso G, et al. Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer (2014) 21:17–25. doi: 10.1530/erc-13-0415
23. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med (2002) 346:1459–66. doi: 10.1056/NEJMoa021052
24. Koopman K, Gaal J, de Kriger RR. Pheochromocytomas and Paragangliomas: New Developments with Regard to Classification, Genetics, and Cell of Origin. Cancers (Basel) (2019) 11:1070. doi: 10.3390/cancers11061070
25. Armstrong R, Sridhar M, Greenhalgh KL, Howell L, Jones C, Landes C, et al. Pheochromocytoma in children. Arch Dis Child (2008) 93:899–904. doi: 10.1136/adc.2008.139121
26. Waguespack SG, Rich T, Grubbs E, Ying AK, Perrier ND, Ayala-Ramirez M, et al. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2010) 95:2023–37. doi: 10.1210/jc.2009-2830
27. Farrugia FA, Charalampopoulos A. Pheochromocytoma. Endocr Regul (2019) 53:191–212. doi: 10.2478/endr-2019-0020
28. Sarathi V. Characteristics of Pediatric Pheochromocytoma/paraganglioma. Indian J Endocrinol Metab (2017) 21:470–4. doi: 10.4103/ijem.IJEM_558_16
29. Pamorakos C, Hamplova B, Preby M, Preby M, Beuschlein F, Tummers H, et al. Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. J Clin Endocrinol Metab (2017) 102:1122–32. doi: 10.1210/jc.2016-3829
30. Burtis CA, Ashwood ER, Bruns DE, Tietz NW. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed. Saunders (2012).

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Park, Kim, Lee, Kim, Jeong, Lee, Cho and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.